Kolexia
Soria Jean-Charles Oncologie médicale
Soria Jean-Charles
Oncologie médicale
Gustave-Roussy
Villejuif, France
1.3 K Activités
16.5 K Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs du poumon Carcinome pulmonaire non à petites cellules Carcinome pulmonaire à petites cellules Carcinomes Métastase tumorale Carcinome épidermoïde Adénocarcinome Tumeurs du sein Mélanome

Collaborateurs

Voir plus
Massard Christophe
Massard Christophe
Gustave-Roussy, Villejuif, France
Besse Benjamin
Besse Benjamin
Gustave-Roussy, Villejuif, France
Hollebecque Antoine
Hollebecque Antoine
Gustave-Roussy, Villejuif, France
Gazzah Anas
Gazzah Anas
Gustave-Roussy, Villejuif, France

Industries

Voir plus
PearlRiver Bio GmbH
1 collaboration(s)
Dernière en 2020
Parexel
1 collaboration(s)
Dernière en 2021
{{person.topindus3.name}}
{{person.topindus3.tot}} collaboration(s)
Dernière en {{person.topindus3.last}}
{{person.topindus4.name}}
{{person.topindus4.tot}} collaboration(s)
Dernière en {{person.topindus4.last}}

Dernières activités

Voir plus
Correction: Metabolomic analyses of COVID-19 patients unravel stage-dependent and prognostic biomarkers.
Cell death & disease   14 février 2024
LDK378 Versus Chemotherapy in Previously Untreated Patients With ALK Rearranged Non-small Cell Lung Cancer: A Phase III Multicenter, Randomized Study of Oral LDK378 Versus Standard Chemotherapy in Previously Untreated Adult Patients With ALK Rearranged (ALK-positive), Stage IIIB or IV, Non-squamous Non-small Cell Lung Cancer
Essai Clinique (Novartis)   22 janvier 2024
FLAURA: A Phase III, Double-blind, Randomised Study to Assess the Safety and Efficacy of AZD9291 Versus a Standard of Care Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor as First Line Treatment in Patients With Epidermal Growth Factor Receptor Mutation Positive, Locally Advanced or Metastatic Non Small Cell Lung Cancer.
Essai Clinique (AstraZeneca)   15 janvier 2024
SAFIR02_Breast: PERSONALIZED MEDICINE GROUP / UCBG UC-0105/1304: SAFIR02_Breast - Evaluation of the Efficacy of High Throughput Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer
Essai Clinique (Unicancer)   09 janvier 2024
Olaparib maintenance versus placebo in platinum-sensitive non-small cell lung cancer: the Phase 2 randomized PIPSeN trial.
British journal of cancer   14 décembre 2023
Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma Subtypes: A Phase II Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma Subtypes
Essai Clinique (MedImmune)   18 octobre 2023
SELECT-2: A Phase II, Double-Blind, Randomised, Placebo-Controlled Study to Assess the Efficacy and Safety of Selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) in Combination With Docetaxel, Compared With Placebo in Combination With Docetaxel, in Patients Receiving Second Line Treatment for Locally Advanced or Metastatic Non Small Cell Lung Cancer (Stage IIIB - IV)
Essai Clinique (AstraZeneca)   12 octobre 2023
1062P Anti-PD1 efficacy in European patients with advanced MSI-H/MMRd non-colorectal cancers
Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023.   01 octobre 2023
Precision medicine in the era of multi-omics: can the data tsunami guide rational treatment decision?
ESMO open   27 septembre 2023
AURA3: A Phase III, Open Label, Randomized Study of AZD9291 Versus Platinum-Based Doublet Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Whose Disease Has Progressed With Previous Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Whose Tumours Harbour a T790M Mutation Within the Epidermal Growth Factor Receptor Gene (AURA3).
Essai Clinique (AstraZeneca)   11 septembre 2023